ClinicalTrials.gg
RecruitingNCT05197192Updated Aug 20, 2026

A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL

A Phase 3 interventional study of Obinutuzumab and Venetoclax in Chronic Lymphocytic Leukemia, sponsored by German CLL Study Group. Recruiting at 30 sites in Germany. Open to participants aged 18 Years to 120 Years. Per ClinicalTrials.gov, last updated 2026-08-20.

Sponsored by German CLL Study Group · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2022; still recruiting 4 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
202
Allocation
Randomized
Ages
18 Years to 120 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 53 studies testing obinutuzumab in Leukemia, Lymphocytic, Chronic, B-Cell — 16 open to participants now, 28 under way, 6 of them phase 3. obinutuzumab · Leukemia, Lymphocytic, Chronic, B-Cell.

Planned enrollment
11th of 53
202 · median 72
Started
2022
with 3 others
Phase 3
13 of 53
4 open now
Primary completion
2028-05
later than 20 of 27 live
Registered
39th of 53
by date
Lead sponsor
3 of 53
German CLL Study Group

Among the 53 studies testing obinutuzumab in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 11th largest by planned enrollment, is one of 4 that started in 2022, is one of 13 in phase 3, reaches primary completion later than 20 of the 27 other live ones, and was the 39th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,039 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 237 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

16 of the 53 studies testing obinutuzumab in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 16 open studies →

About obinutuzumab

obinutuzumab: first FDA approval 2013 (GAZYVA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 151 (81%) set no upper age limit and 15 (8%) stop at 75 or younger; 18 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 120 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies testing obinutuzumab in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

This multicenter, prospective, open-label, randomized, superiority phase 3 study is designed to demonstrate that treatment with a triple combination of acalabrutinib, obinutuzumab and venetoclax (GAVe) prolong the progression-free survival (PFS) as compared to treatment with the combination of obinutuzumab and venetoclax (GVe) in pa-tients with high risk CLL (defined as having at least one of the follow-ing risk factors: 17p-deletion, TP53-mutation, complex karyotype or an unmutated IGHV-gene status).

Read the detailed description

CLL is the most frequent leukemia in industrialized countries. International guidelines agree on diagnosis and management of this disease. The clinical course of CLL is highly variable and can be predicted by clinical staging (according to Rai and Binet) as well as genetic, serum markers and risk models. This study is designed for a randomized comparison of two different, non-chemotherapeutic and fixed-duration modalities for patients with high risk chronic lymphocytic leukemia (CLL) and addresses a high medical need, since high risk-CLL represents a so far incurable, aggressive cancer. The high risk-group of CLL patients can be identified by molecular characteristics, allowing the inclusion of a clearly described group of patients: 17p-deletion, TP53-mutation and/or complex karyotype.TP53 defects are the strongest prognostic factors for non-response to chemotherapy. Patients harboring TP53 defects should be treated with chemotherapy-free regimens. Complex karyotype (CKT), defined as the presence of three or more chromosomal aberrations in two or more metaphases is associated with a poorer outcome in various hematologic malignancies, including chronic lymphocytic leukemia (CLL). In CLL, CKT is one of several well established adverse prognostic factors, comparable to 17p-deletion, TP53-mutation or unmutated IGHV status. Depending on age and prior exposure to chemotherapy, 10-30% of patients with CLL exhibit CKT. A broad body of evidence has suggested a predictive prognostic value of CKT. Despite considerable advances with chemoimmunotherapy in the treatment of frontline as well as relapsed/refractory (r/r) CLL, outcome of patients with CKT remains poor. To date, a randomized comparison to optimize the treatment of patients with high risk disease defined as either the presence of TP53 aberrations or CKT, by novel agents has not been performed. Patients with high risk CLL (TP53-defects and/or CKT) have a poor outcome with chemoimmunotherapy and do not benefit to the same extent from approved regimen such as continuous treatment of ibrutinib or 12 months treatment with obinutuzumab plus venetoclax. Monotherapy with BTK-inhibitor is less effective in those patients as compared with patients without high risk disease. Venetoclax combined with the anti-CD20 monoclonal antibody obinutuzumab offers a highly effective fixed-duration treatment option with a manageable toxicity profile. The recent results of the CLL14 study define a new standard of a fixed 12-months treatment with obinutuzumab and venetoclax in previously untreated patients yielding a major benefit also for patients with high risk disease as compared to chemoimmunotherapy. However, high risk patients appear to progress earlier than low risk patients and the therapy is not clearly curative so far. Acalabrutinib is a second generation, selective BTK inhibitor which has shown promising overall response rates in patients with relapsed CLL or patients intolerant to ibrutinib. The development of acalabrutinib focussed on minimization of off-target activity. Results of a three-arm study investigating the combination of acalabrutinib plus obinutuzumab versus acalabrutinib alone versus chlorambucil plus obinutuzumab (NCT02475681) showed a substantial improvement of PFS for the combination arm and the monotherapy versus the standard chemoimmunotherapy regimen. The addition of a BTK-inhibitor, such as acalabrutinib to obinutuzumab and venetoclax has the potential to result in a better outcome, because synergistic effects have been reported between BTK inhibitors and B-cell lymphoma 2 (BCL-2) inhibitors or for BCL-2 inhibitors and monoclonal antibodies. Synergistic effects, which are expected to reduce early progressions or insufficient responses, are in particular important for this high risk population. The triple combination of acalabrutinib, obinutuzumab (or rituximab) and venetoclax has been investigated in a phase 1 b- study and had a tolerable safety profile with minimal to no drug-drug interactions, results of a phase 2 trial studying the same combination showed that the triple combination was highly active with 78% undetectable MRD levels in the bone marrow . Currently, the GCLLSG conducts phase 2 studies, investigating a triple combination consisting of BTK- and Bcl2-inhibitors and monoclonal antibodies (CLL2GIVe: NCT02758665; CLL2BAAG: NCT03787264) and a large phase 3 trial with one experimental arm with a triple combination (CLL13, NCT02950051) but results are not yet published. Acalabrutinib, venetoclax and obinutuzumab is now being studied in a registrational phase 3 trial CL-311 (NCT03836261) against the current standard of chemoimmunotherapy (fludarabine/cyclophosphamide/rituximab (FCR), bendamustine/rituximab (BR) in patients without 17p-deletion or TP53-mutation. Acalabrutinib is indicated in Germany as monotherapy or in combination with obinutuzumab for the treatment of adult patients with treatment-naive chronic lymphocytic leukemia (CLL) and as monotherapy for the treatment of adult patients with relapsed chronic lymphocytic leukemia (CLL).

03

Conditions studied

  • Chronic Lymphocytic Leukemia

Keywords

  • CLL
  • high risk
  • tp53 aberration
  • complex karyotype
  • unmutated IGHV gene status
04

Who can participate

Ages eligible
18 Years to 120 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented CLL/SLL requiring treatment according to iwCLL criteria
  • Age at least 18 years
  • At least one of the following risk factors: 17p-deletion, TP53-mutation, complex karyotype (defined as defined as the presence of 3 or more chromosomal aberrations in 2 or more metaphases) or an unmutated IGHV gene status.
  • ≥ six months
  • Adequate bone marrow function indicated by a count >30 x10\^9/l
  • ≥ 30ml/min
  • Adequate liver function as indicated by a total ≤ 2 x, / ALT ≤ 2.5 x the institutional value, unless directly attributable to the patient's CLL or to Gilbert's Syndrome
  • Negative testing for (HbsAg negative and anti-HBc negative; patients positive for anti-HBc may be included if PCR for HBV DNA is negative and HBV-DNA PCR is performed every month until 12 months after last treatment cycle),or (negative testing for hepatitis C RNA within 6 wee
  • ks prior to registration for study screening (i.e. PCR only required when serology was positive))
  • (Eastern Cooperative Oncology Group Performance Status) status 0-2

Exclusion criteria

Exclusion Criteria:

  • Any prior CLL-specific therapies (except treatment administered due to necessary immediate intervention; within the last 10 days before start of study treatment, only dose equivalents up to 20 mg prednisolone are permitted)
  • Absence of high risk disease (17p-deletion, TP53-mutation complex karyotype
  • An individual organ/system impairment score of 4 as assessed by the CIRS definition (e.g. advanced cardiac disease ( class 3 or 4) limiting the ability to receive the study treatment or any other life-threatening illness, medical condition or organ system dysfunction that, in the investigator´s opinion, could compromise the patients safety or interfere with the absorption or metabolism of the study drugs (e.g. inability to swallow tablets or impaired resorption in the gastrointestinal tract)
  • Transformation of CLL (Richter transformation)
  • other than CLL currently requiring systemic therapies
  • Uncontrolled or active infection of /PML or any other active infection
  • Anticoagulant therapy with warfarin or phenoprocoumon
  • Pregnant women and nursing mothers
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
202 participants (estimated)

Study arms

  • Experimental
    GAVe-Arm

    Acalabrutinib plus Venetoclax plus Obinutuzumab plus (GAVe)

    Drug: Obinutuzumab · Drug: Venetoclax · Drug: Acalabrutinib

  • Experimental
    GVe-Arm

    Obinutuzumab plus Venetoclax (GVe)

    Drug: Obinutuzumab · Drug: Venetoclax

Interventions

  • Obinutuzumab i.v. infusion: Cycle 1 Day 1: Obinutuzumab 100 mg i.v. Cycle 1 Day 1 (or 2): Obinutuzumab 900 mg i.v. Cycle 1 Day 8: Obinutuzumab 1000 mg i.v. Cycle 1 Day 15: Obinutuzumab 1000 mg i.v. Cycles 2-6: Day 1: Obinutuzumab 1000 mg i.v.

    Also known as: Gazyva, Gazyvaro

  • Venetoclax p.o.: Cycle 1: Days 22-28: Venetoclax 20 mg (2 x 10 mg) Cycle 2: Days 1-7: Venetoclax 50 mg (1 x 50 mg) Cycle 2:Days 8-14: Venetoclax 100 mg (1 x 100 mg) Cycle 2:Days: 15-21: Venetoclax 200 mg (2 x 100 mg) Cycle 2:Days: 22-28: Venetoclax 400 mg (4 x 100 mg) Cycles 3-12: Days 1-28: Venetoclax 400 mg (4 x 100 mg)

    Also known as: Venclexta, Venclyxto

  • Cycles 15-24: Days 1-28: 100 mg acalabrutinib twice daily p.o. approx. every 12 hrs (corresponding to a total daily dose of 200 mg).

    Also known as: Calquence

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS)

    The study is designed to demonstrate that 14 cycles of treatment with GAVe followed by up to 10 cycles maintenance with acalabrutinib for patients with detectable MRD at cycle 14 day 14 prolong PFS as compared to 12 cycles of treatment with GVe in patients with high risk CLL (defined as hav-ing at least one of the following risk factors: 17p-deletion, TP53- mutation or complex karyotype).

    Time frame: 50 months after FPI

Secondary outcomes

  1. Minimal residual disease (MRD) levels

    Minimal residual disease (MRD) levels in the peripheral blood (PB) and in the bone marrow (BM) at final restaging ((Staging 5) cycle 15 day 1 for patients in GVe study arm, cycle 14 day 14 for patients in GAVe study arm)

    Time frame: 50 months after FPI

  2. MRD in PB at cycle 27 day 1

    MRD in PB at cycle 27 day 1 for all patients (end of maintenance for patients in GAVe study arm, who had detectable MRD levels after 14 cycles of GAVe-treatment)

    Time frame: 50 months after FPI

  3. Overall response rate

    Overall response rate (ORR; as per iwCLL guidelines) at cycle 15

    Time frame: 50 months after FPI

  4. Complete response rate

    Complete response rate (CRR; as per iwCLL guidelines) at cycle 15

    Time frame: 50 months after FPI

  5. Overall Survival (OS)

    Overall Survival (OS)

    Time frame: 50 months after FPI

  6. Event-free survival (EFS)

    Event-free survival (EFS)

    Time frame: 50 months after FPI

  7. Duration of response (DOR)

    Duration of response (DOR)

    Time frame: 50 months after FPI

  8. Time to next treatment (TTNT)

    Time to next treatment (TTNT)

    Time frame: 50 months after FPI

Other outcomes

  1. Correlation between MRD in PB/BM and PFS/OS

    Time-to-event analyses will be calculated accordiung to MRD levels in peripheral bloos and bone marrow respectively.

    Time frame: 50 months after FPI

  2. MRD by methods other than flow cytometry (ddPCR)

    New methods of MRD measurements (ddPCR) will be compared with the standard method (flow cytometry )

    Time frame: 50 months after FPI

  3. Correlation between MRD in PB and BM

    MRD levels in the peripheral blood and in the bone marrow will be statistically compared.

    Time frame: 50 months after FPI

  4. Longitudinal Analysis of European Organisation for Research and Treatment of Cancer(EORTC): Quality of Life Questionnaire (QLQ-C30) at defined timepoints

    Outcome measure: scores of EORTC QLQ-C30 and QLQ-CLL17 Questionnaires at defined timepoints will be analyzed and compared to baseline level for each patient. Scoring of the QLQ-C30 is performed according to QLQ-C30 Scoring manual. All of the scales and single-item measures range in score from 0 to 100. Higher score for the functioning scales and global health status denote a better level of functioning (i.e. a better state of the patient), while higher scores on the symptom and single-item scales indicate a higher level of symptoms (i.e. a worse state of the patient)

    Time frame: 50 months after FPI

07

Study locations

30 of 30 sites recruiting
  • Helios Klinikum Bad Saarow
    Bad Saarow, 15526, Germany
    Recruiting
    • Daniel Schöndube · Contact
  • DRK Kliniken Berlin Köpenick
    Berlin, 12559, Germany
    Recruiting
    • Christian Neumann · Contact
  • Ev. Diakoniekrankenhaus
    Bremen, 28239, Germany
    Recruiting
    • Ralf Ulrich Trappe · Contact
  • Universitätsklinik Köln
    Cologne, 50937, Germany
    Recruiting
    • Barbara Eichhorst · Contact
  • St. Johannes Hospital
    Dortmund, 44137, Germany
    Recruiting
    • Ralf Meyer · Contact
  • Marien Hospital Düsseldorf
    Düsseldorf, 40479, Germany
    Recruiting
    • Stefanie Gröpper · Contact
  • St. Antonius-Hospital
    Eschweiler, 52249, Germany
    Recruiting
    • Peter Staib · Contact
  • Universitaetsklinikum Essen
    Essen, 45147, Germany
    Recruiting
    • Julia von Tresckow · Contact
  • Katholisches Krankenhaus Hagen - St. Josefs Hospital
    Hagen, 58097, Germany
    Recruiting
    • Doris Kraemer · Contact
  • Universitaetskliniken des Saarlandes
    Homburg, 66424, Germany
    Recruiting
    • Jörg Bittenbring · Contact
  • Klinikum Idar-Oberstein SHG
    Idar-Oberstein, 55743, Germany
    Recruiting
    • Johannes Schneider · Contact
  • Staedtisches Klinikum Karlsruhe
    Karlsruhe, 76133, Germany
    Recruiting
    • Henriette Huber · Contact
  • Universitaetsklinikum Schleswig-Holstein Campus Kiel
    Kiel, 24116, Germany
    Recruiting
    • Matthias Ritgen · Contact
  • Klinikum Landshut
    Landshut, 84034, Germany
    Recruiting
    • Christian Bogner · Contact
  • Klinikum Lippe-Lemgo
    Lemgo, 32657, Germany
    Recruiting
    • Karin Heinisch · Contact
  • St Vincenz Krankenhaus
    Limburg, 65549, Germany
    Recruiting
    • Thomas Neuhaus · Contact
  • Universitaetsklinikum Magdeburg
    Magdeburg, 39120, Germany
    Recruiting
    • Ana Maria Waldleben · Contact
  • Klinikum Hochsauerland - St. Walburga Krankenhaus
    Meschede, 59872, Germany
    Recruiting
    • Mohammad Wattad · Contact
  • KH Kliniken Maria Hilf
    Mönchengladbach, 41063, Germany
    Recruiting
    • Ulrich Graeven · Contact
  • Krankenhaus Muenchen-Schwabing
    Munich, 80804, Germany
    Recruiting
    • Clemens Wendtner · Contact
  • Klinikum Rechts der Isar - Technische Universitaet Muenchen
    Munich, 81675, Germany
    Recruiting
    • Simon Heidegger · Contact
  • Kliniken Ostalb, Stauferklinikum Schwäbisch Gmünd
    Mutlangen, 73557, Germany
    Recruiting
    • Holger Hebart · Contact
  • Klinikum Oldenburg
    Oldenburg, 26133, Germany
    Recruiting
    • Andrea Renzelmann · Contact
  • Brüderkrankenhaus St. Josef Paderborn
    Paderborn, 33098, Germany
    Recruiting
    • Tobias Gaska · Contact
  • Universitätsklinik Rostock
    Rostock, 18057, Germany
    Recruiting
    • Sebastian Böttcher · Contact
  • Caritas-Klinik St. Theresia
    Saarbrücken, 66113, Germany
    Recruiting
    • Michael Clemens · Contact
  • Klinikum Sindelfingen-Böbingen
    Sindelfingen, 71065, Germany
    Recruiting
    • Markus Ritter · Contact
  • Marienhospital Stuttgart
    Stuttgart, 70199, Germany
    Recruiting
    • Claudio Denzlinger · Contact
  • Universitaetsklinik Tuebingen
    Tübingen, 72076, Germany
    Recruiting
    • Stefan Wirths · Contact
  • Universitätsklinik Ulm
    Ulm, 89081, Germany
    Recruiting
    • Christof Schneider · Contact
08

References and documents

Related links

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2022 (actual). Primary completion is estimated for May 2028, 73 months after the start.

Of 83 phase 3 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 76. This study's planned 73 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2021
First posted
Jan 19, 2022
StartActual
Apr 19, 2022
Primary completionEst.
May 2028
CompletionEst.
May 2028
Last update
Aug 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05197192
Lead sponsor
German CLL Study Group
Collaborators
AstraZeneca
Responsible party
Sponsor
First posted
Jan 19, 2022
Start date
Apr 19, 2022
Primary completion
May 2028 (estimated)
Completion
May 2028 (estimated)
Last update
Aug 20, 2026

Study contacts

Barbara Eichhorst, MD, Prof.
Contact
barbara.eichhorst@uk-koeln.de
+4922147888220
Anna Fink, MD
Contact
anna-maria.fink@uk-koeln.de
+4922147888220
Barbara Eichhorst, MD, Prof.
principal investigator · Department I of Internal Medicine, University Hospital Cologne

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Obinutuzumab · Venetoclax

Start the discussion